Designing novel rational Treg and tumor microenvironment-based therapies
Despite transformative advancement in the last decades in cancer immunotherapy, there is clearly a gap in our understanding as not all cancers and not all patients respond to these treatments, which focus mainly on targeting of specific markers expressed by tumor cells, the suppression or enhancement of specific effector cell receptors or the engineering of targeting cytotoxic agents.
Read more